E

    EXAS (EXAS)

    Official site

    DIAGNOSTICS & RESEARCH

    $104.91
    +0.00 (+0.00%)

    Last updated: Mar 24, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(28/38)
    Avg Surprise
    +7.62%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$0.05
    Range$0.05 - $0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$0.10+106.2%
    60d ago$0.10+106.2%
    30d ago$0.02-53.4%
    7d ago$0.02-53.4%
    Current$0.05
    Revenue Consensus
    $842M
    Range$826M - $865M
    7 analysts
    Jun 30, 2026
    EPS Consensus$0.28
    Range$0.28 - $0.28
    1 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$0.31+9.1%
    60d ago$0.31+9.1%
    30d ago$0.30+8.3%
    7d ago$0.30+8.3%
    Current$0.28
    Revenue Consensus
    $917M
    Range$880M - $944M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$0.28---
    Mar 26EST
    		-$0.05---
    Dec 25
    		$-0.21$0.08-362.50%Miss+12.6%
    Sep 25
    		$0.24$0.16+50.00%Beat+214.3%
    Jun 25
    		$-0.01N/A+92.31%Beat+83.3%
    Mar 25
    		$-0.36$-0.47+23.83%Beat+33.7%
    Dec 24
    		$-0.24$-0.33+27.74%Beat+44.1%
    Sep 24
    		$-0.21$-0.21+0.00%Beat+34.4%
    Jun 24
    		$-0.06N/A+75.00%Beat+82.9%
    Mar 24
    		$-0.54$-0.41-31.71%Miss-54.3%
    Dec 23
    		$-0.43$-0.36-19.44%Miss+23.2%
    Sep 23
    		$-0.32$-0.43+25.58%Beat+56.8%
    Jun 23
    		$-0.35$-0.41+14.63%Beat+62.4%
    Mar 23
    		$-0.35$-0.66+46.97%Beat+70.3%
    Dec 22
    		$-0.56$-0.78+28.21%Beat+56.3%
    Sep 22
    		$-0.74$-1.05+29.52%Beat+0.0%
    Jun 22
    		$-0.93$-1.04+10.58%Beat-22.4%
    Mar 22
    		$-1.18$-1.04-13.46%Miss-1585.7%
    Dec 21
    		$-1.28$-0.88-45.45%Miss-1180.0%
    Sep 21
    		$-0.74$-0.83+10.84%Beat-1380.0%
    Jun 21
    		$-0.76$-0.72-5.56%Miss-10.1%
    Mar 21
    		$-0.07N/A+92.55%Beat+89.4%
    Dec 20
    		$-0.10N/A+61.54%Beat+86.8%
    Sep 20
    		$-0.05N/A+91.23%Beat+83.9%
    Jun 20
    		$-0.69$-0.65-6.15%Miss-130.0%
    Mar 20
    		$-0.66$-0.52-26.92%Miss+0.0%
    Dec 19
    		$-0.76$-0.36-111.11%Miss-72.7%
    Sep 19
    		$-0.31$-0.41+24.39%Beat+16.2%
    Jun 19
    		$-0.30$-0.56+46.43%Beat+0.0%
    Mar 19
    		$-0.66$-0.65-1.54%Miss-100.0%
    Dec 18
    		$-0.44$-0.48+8.33%Beat-144.4%
    Sep 18
    		$-0.37$-0.43+13.95%Beat-60.9%
    Jun 18
    		$-0.30$-0.32+6.25%Beat-11.1%
    Mar 18
    		$-0.33$-0.38+13.16%Beat-3.1%
    Dec 17
    		$-0.18$-0.24+25.00%Beat+47.1%
    Sep 17
    		$-0.23$-0.30+23.33%Beat+36.1%
    Jun 17
    		$-0.27$-0.35+22.86%Beat-
    Mar 17
    		$-0.32$-0.41+21.95%Beat-
    Dec 16
    		$-0.34$-0.39+12.82%Beat-
    Sep 16
    		$-0.36$-0.42+14.29%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$104.04
    SMA 20$103.72
    SMA 50$103.14
    SMA 200$74.80
    EMA 10$104.23
    EMA 20$103.86
    EMA 50$101.87
    EMA 200$81.73

    MACD

    Line: 0.48Signal: 0.38Hist: 0.10

    ADX

    ADX: 46.8+DI: 38.4-DI: 6.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down32.0
    PSAR$103.49

    Bollinger Bands

    Upper Band$104.83
    Lower Band$102.61
    %B Position214%(Upper)
    Band Width1.03

    RSI (14-Day)

    Overbought
    76.4

    Momentum Oscillators

    Stoch %K96.1
    Stoch %D92.8
    Williams %R-4.0
    ROC (10d)1.5%
    Momentum1.54
    CCI (20d)192.8
    MFI (14d)79.6

    Volatility Measures

    ATR (14d)$0.32(0.3%)
    StdDev (20d)0.56
    Hist Vol4.2%(Low)

    Volume Flow

    VWAP$104.91
    OBV228.8M
    AD Line-50.7M
    CMF (20d)-0.162

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol RatioN/A
    VWMA (20d)$104.03

    Pivot Points

    R3$104.91
    R2$104.91
    R1$104.91
    Pivot Point$104.91
    S1$104.91
    S2$104.91
    S3$104.91

    Advanced Oscillators

    TSI39.85
    Ultimate Osc73.4
    KST9.22

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$878.38M$850.74M$811.09M$706.78M$713.42M$708.65M$699.26M$637.52M$646.88M$628.34M$622.09M$602.45M
    Cost of Revenue$262.56M$266.81M$248.63M$206.24M$220.83M$217.17M$210.95M$191.20M$255.18M$168.53M$156.99M$156.87M
    Gross Profit$615.83M$583.93M$562.45M$500.55M$492.59M$491.49M$488.32M$446.32M$391.70M$459.81M$465.10M$445.58M
    Operating Expenses$698.42M$609.47M$564.60M$596.56M$1.37B$530.89M$514.57M$553.01M$459.55M$452.96M$542.03M$522.67M
    R&D$191.50M$117.29M$108.90M$105.31M$97.71M$101.49M$121.14M$110.87M$115.97M$111.45M$104.09M$95.42M
    SG&A$217.99M$241.41M$208.58M$220.69M$191.11M$193.54M$177.52M$219.65M$127.64M$217.39M$237.97M$217.29M
    Operating Income$-82,595,000$-25,545,000$-2,148,000$-96,010,000$-876,351,000$-39,403,000$-26,257,000$-106,692,000$-67,841,000$6.85M$-76,929,000$-77,091,000
    Interest Income$0$0$0$0$0$0$0$0$0$2.06M$4.83M$0
    Interest Expense$9.76M$9.79M$9.84M$9.98M$9.58M$9.61M$-111,000$7.94M$7.87M$7.87M$7.82M$-4,107,000
    Income Before Tax$-85,083,000$-17,757,000$-57,000$-100,991,000$-875,966,000$-37,428,000$-14,345,000$-108,422,000$-50,376,000$1.04M$-79,919,000$-72,494,000
    Income Tax Expense$872,000$1.84M$1.13M$224,000$-11,381,000$808,000$1.46M$1.81M$-610,000$249,000$1.11M$1.66M
    Net Income$-85,955,000$-19,594,000$-1,185,000$-101,215,000$-864,585,000$-38,236,000$-15,808,000$-110,228,000$-49,766,000$794,000$-81,026,000$-74,151,000
    EBITDA$-18,971,000$47.91M$65.06M$-36,952,000$-823,204,000$26.95M$38.54M$-46,536,000$-13,669,000$59.10M$-26,490,000$-27,348,000
    EBIT$-75,324,000$-7,968,000$9.78M$-91,013,000$-876,351,000$-27,821,000$-14,456,000$-100,479,000$-67,841,000$6.85M$-76,929,000$-77,091,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EXAS

    News

    Exact Sciences stock trades steady as colorectal screening momentum meets earnings pressure

    Exact Sciences stock is stable, balancing strong growth in its colorectal cancer screening business with ongoing net losses. Investors are keenly observing total revenue growth, which has been in double digits, and the company's progress towards profitability, as operating expenses remain high despite improved adjusted earnings metrics. The company's future valuation depends on its ability to sustain revenue growth while mitigating losses and managing competition and regulatory changes in the diagnostics market.

    Ad-hoc-news.de•7/27/26•
    Neutral

    Exact Sciences stock trades steadily as revenue grows and screening portfolio expands

    Exact Sciences stock is maintaining steady trade due to increasing revenue and an expanding cancer screening portfolio, which is enhancing its long-term profile for investors. The company's flagship Cologuard test drives significant revenue, complemented by its precision oncology segment, diversifying its revenue base. The article highlights the balance between revenue growth, cost management, and continuous innovation in a competitive and regulated healthcare market as key factors for investor perception and long-term value.

    Ad-hoc-news.de•7/24/26•
    Bullish

    Exact Sciences stock trades steady as revenue growth and screening demand support valuation

    Exact Sciences' stock is holding steady, driven by strong double-digit revenue growth and increasing demand for its diagnostic tests, particularly Cologuard for colorectal cancer screening and Oncotype DX for precision oncology. The company's recent fiscal 2023 results showcased a nearly 19% revenue increase to $2.5 billion, with improved gross margins and adjusted EBITDA, despite continued heavy investment in R&D. These factors, alongside a large addressable market and strategic pipeline developments, support its valuation amidst the competitive diagnostics sector.

    Ad-hoc-news.de•7/23/26•
    Bullish

    Exact Sciences stock trades near recent highs as screening demand supports revenue growth

    Exact Sciences' stock is trading near recent highs, driven by strong demand for its cancer screening tests, particularly the Cologuard colorectal cancer test. The company has reported double-digit revenue growth and narrowing losses, supported by an expanding US diagnostics footprint and a broadening oncology diagnostics portfolio. Exact Sciences continues to focus on improving operating metrics, investing in R&D for new tests, and managing competitive dynamics in the diagnostics market.

    Ad-hoc-news.de•7/22/26•
    Bullish

    Exact Sciences stock trades steadily as screening growth offsets guidance reset

    Exact Sciences' stock performance is driven by a balance of strong cancer screening demand and adjusted revenue guidance. The company’s flagship products, Cologuard and Oncotype DX, continue to show significant growth, with Cologuard revenue exceeding targets and contributing to improved margins. Despite a slight reduction in 2024 revenue guidance, the company emphasizes a path towards enhanced profitability through operational efficiencies and scale economics.

    ad-hoc-news.de•7/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About EXAS

    Does EXAS pay dividends?
    EXAS (EXAS) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In